Clinical Trial Update: A Phase II, Open-Label Study of Clofarabine in Paediatric Patients With Refractory/Relapsed Acute Lymphoblastic Leukaemia [Phase 2]

View source ↗

Summary

Phase II, open-label study evaluating clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. The trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• Clolar (Clofarabine)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Acute Lymphoblastic Leukemia | Phase 2 | Status: COMPLETED